<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337986</url>
  </required_header>
  <id_info>
    <org_study_id>Ampyra Vision 2011 RTN</org_study_id>
    <secondary_id>WU HRPO# : 201104126</secondary_id>
    <nct_id>NCT01337986</nct_id>
  </id_info>
  <brief_title>Ampyra for Optic Neuritis in Multiple Sclerosis</brief_title>
  <official_title>Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and
      blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the
      hypothesis that dalfampridine, when administered to subjects with incomplete visual recovery
      after optic neuritis from MS, will result in symptomatic improvement in visual function. The
      study will consist of one screening/baseline visit, one visit during treatment with active
      drug, and one visit on placebo. After the baseline visit, subjects will be randomly assigned
      to receive study medication or placebo for the first three weeks, followed by a two week
      wash-out, and then treatment reallocation for the latter three weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optic neuritis (ON) is the presenting feature of multiple sclerosis (MS) in 15% of cases, and
      occurs over the disease course in 50% of patients.1-3 Vision remains a major concern for MS
      patients, as visual dysfunction leads to lower quality of life.4-6 Despite the high
      prevalence of ON in MS, treatment and management options remain limited. Although intravenous
      glucocorticoids are employed to aid recovery of an acute episode of ON, no convincing
      evidence supports their efficacy in altering the degree of long-term recovery.7 Although some
      individuals with ON can have a dramatic recovery from blindness, ON often impairs visual
      function permanently. In the Optic Neuritis Treatment Trial, 63% reported that vision had not
      returned to normal after 6 months, and 20% had vision worse than 20/20 after 5 years of
      follow-up.8, 9 Visual impairment creates difficulties at home and work, leading to decreased
      independence and impaired mobility within the community. Visual dysfunction in combination
      with MS impairments within cerebellar and proprioceptive systems can be particularly
      disabling.

      Optic neuritis classically impairs one's ability to read print or a computer screen, to drive
      in bright or low light, and to appreciate colors and contrasts. Unfortunately, when optic
      neuritis results in lasting impairment, there are no pharmacologic therapies to restore
      vision. Low vision specialists may provide magnifying glasses, brighter lights, and advice to
      optimize the position of objects at home and in the workplace. Better treatment options are
      needed to improve visual function.

      Ampyra (dalfampridine) is a potassium-channel antagonist, with a mechanism-of-action to
      improve nerve conduction in demyelinated axons, resulting in an electrophysiologic and
      clinical benefit.10-22 Demyelinated axons within the anterior visual pathway would be a prime
      and ideal target to study the effects of Ampyra. In fact, Stefoski et al demonstrated visual
      function benefit in an open-label study of IV 4-aminopyridine in 12 subjects.21 The optic
      nerves are a well-defined white-matter tract, commonly affected in MS, and with clear
      clinical outcome measures. In addition, visual evoked potentials (VEPs) can be included
      within the study design as a secondary endpoint, to confirm improved nerve conduction.
      Because VEPs are such a precise, reliable, and accepted measure of demyelination, the
      anterior visual pathway is the ideal in vivo human system to study the electro-physiologic
      effects of a therapeutic such as Ampyra.

      Hypothesis 1: Dalfampridine treatment will improve visual function, measured by the 5% ETDRS
      contrast sensitivity chart, in subjects with long-term visual impairment secondary to optic
      neuritis from MS.

      Hypothesis 2: Dalfampridine treatment will reduce visual evoked potential P100 latency
      following remote optic neuritis.

      Hypothesis 3: Dalfampridine treatment will result in an improvement in secondary endpoints,
      including visual fields, high contrast visual acuity, color vision, and quality of life.

      The study will be conducted at the Department of Neurology and Neurosurgery, Washington
      University School of Medicine, St. Louis, the institution at which Dr. Naismith is based. The
      MS patients will come from the 1800 active MS patients in our clinic and the 3500 in the St.
      Louis area.

      Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and
      blinded cross-over trial of dalfampridine of 8 weeks duration (Table 1). The study will test
      the hypothesis that dalfampridine, when administered to subjects with incomplete visual
      recovery after optic neuritis from MS, will result in symptomatic improvement in visual
      function. The study will consist of one screening/baseline visit, one visit during treatment
      with active drug, and one visit on placebo. After the baseline visit, subjects will be
      randomly assigned to receive study medication or placebo for the first three weeks, followed
      by a two week wash-out, and then treatment reallocation for the latter three weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Per Protocol Analysis to assess differences in EDTRS 5% Contrast Sensitivity (LogMAR) Scores at visits 2 and 3 Relative to Visit 1 on patients taking Dalfampridine vs Placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Per Protocol Analysis to assess difference in number of letters on the EDTRS 5% Contrast Sensitivity (LogMAR) Chart scores at visits 2 and 3 Relative to Visit 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Improvement from baseline scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Change in the number of letters able to read while on Dalfampridine and Placebo relative to their baseline scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes That Improved by One-line (5 Letters)</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Percentage of eyes that improved by one-line (5 letters) on the 5% contrast sensitivity chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Evoked Potential P100 Latency Per Treatment Arm</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Visual evoked potential 60min P100 latency on dalfampridine vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Odds Ratio Quartile of Visual Field Index</measure>
    <time_frame>Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - post intervention 1) and Visit 3 (Week 8 - post intervention 2)</time_frame>
    <description>The Visual Field Index (VFI) is a global index that assigns a number between 1% to 100% based on an aggregate percentage of visual function, with 100% being a perfect age-adjusted visual field.
Probability of falling in the best quartile for visual field (VFI) measures (Q1), relative to the three next quartiles for worse VFIs (Q2-4), while on Dalfampridine vs Placebo. Due to the clustered observations at different times in a cross-over design, the visual field data is not suited to a normal theory model and should not be expressed as a continuous variable. Thus, a categorical model that uses a multinomial distribution for measurement of 4 categories was selected for proper statistical modeling, with results expressed as odds ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Color Vision Total Error Score From Baseline Based Upon the Farnsworth Munsell Hue 100 Sort Test (FM100).</measure>
    <time_frame>Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - postintervention 1) and Visit 3 (Week 8 - post intervention 2)</time_frame>
    <description>Dalfampridine will change color vision Total Error Scores from baseline on the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 color palettes in the correct order based upon color hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score greater than 500 indicates virtually no color discrimination. An error score of 0 indicates no errors in ordering the hues. A Total Error Score of 0 to 128 could be seen in a normal population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dalfampridine Effect on Quality of Life Change From Baseline.</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Dalfampridine treatment will result in change in quality of life. The National Eye Institute Visual Function Questionnaire consists of 25 questions characterizing visual function at home and in the community. Score ranges from 100 (best) to 0 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1</measure>
    <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
    <description>Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 on Dalfampridine vs Placebo. Pelli-Robson is scored based upon the numbers read on the chart converted to LogMAR units. The scale is 0.00 (worst) to 2.35 (best).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Group B: Dalfampridine First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: Dalfampridine Second</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalfampridine/Placebo</intervention_name>
    <description>Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
    <arm_group_label>Group B: Dalfampridine First</arm_group_label>
    <other_name>Ampyra (R)</other_name>
    <other_name>Fampridine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/Dalfampridine</intervention_name>
    <description>Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
    <arm_group_label>Group A: Dalfampridine Second</arm_group_label>
    <other_name>Ampyra (R)</other_name>
    <other_name>Fampridine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria are:

          1. At least one previous clinical episode of optic neuritis,

          2. the last episode of ON must have occurred at least 12 months prior to study entry,

          3. clinically definite MS, defined by the revised McDonald criteria, 23

          4. ages 18-70,

          5. visual acuity greater than or equal to 20/30

          6. must be able to read at least 2 of the 5 letters on the top line of the 5% ETDRS chart
             (logMAR 0.96) at 3 meters, 2 meters or 1 meter, and

          7. must have sufficient cognitive function to understand the consent process and to
             reliably perform all clinical assessments

        Exclusion criteria are:

          1. Any ophthalmologic condition, other than ON, which can affect vision, including
             nystagmus in primary position of gaze,

          2. history of seizures or spells with altered level of consciousness,

          3. pregnancy or breast feeding,

          4. an MS exacerbation or use of glucocorticoids within 3 months of entry,

          5. a history of moderate to severe renal insufficiency,

          6. previous use of 4-aminopyridine, in any formulation, in the prior 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert T Naismith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University (John L. Trotter MS Center)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neuro.wustl.edu/research/mscenter/</url>
    <description>John L. Trotter MS Center, Washington University School of Medicine &amp; Barnes Jewish Hospital</description>
  </link>
  <reference>
    <citation>Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005 Feb;4(2):111-21. Review.</citation>
    <PMID>15664543</PMID>
  </reference>
  <reference>
    <citation>Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005 Jun;139(6):1101-8. Review.</citation>
    <PMID>15953446</PMID>
  </reference>
  <reference>
    <citation>Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006 Mar 23;354(12):1273-80. Review.</citation>
    <PMID>16554529</PMID>
  </reference>
  <reference>
    <citation>Ma SL, Shea JA, Galetta SL, Jacobs DA, Markowitz CE, Maguire MG, Balcer LJ. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol. 2002 May;133(5):686-92.</citation>
    <PMID>11992867</PMID>
  </reference>
  <reference>
    <citation>Noble J, Forooghian F, Sproule M, Westall C, O'Connor P. Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients. Am J Ophthalmol. 2006 Sep;142(3):464-8.</citation>
    <PMID>16935592</PMID>
  </reference>
  <reference>
    <citation>Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, Nano-Schiavi ML, Cutter GR, Maguire MG, Balcer LJ. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):767-72. doi: 10.1136/jnnp.2008.165449. Epub 2009 Feb 23.</citation>
    <PMID>19240050</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581-8.</citation>
    <PMID>1734247</PMID>
  </reference>
  <reference>
    <citation>Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. Arch Ophthalmol. 1997 Dec;115(12):1545-52.</citation>
    <PMID>9400788</PMID>
  </reference>
  <reference>
    <citation>Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol. 1997 Mar;17(1):18-23; quiz 24-8.</citation>
    <PMID>9093956</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.</citation>
    <PMID>19249634</PMID>
  </reference>
  <reference>
    <citation>Fujihara K, Miyoshi T. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci. 1998 Jul 15;159(1):102-6.</citation>
    <PMID>9700711</PMID>
  </reference>
  <reference>
    <citation>Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997 Apr;48(4):817-21.</citation>
    <PMID>9109861</PMID>
  </reference>
  <reference>
    <citation>Davis FA, Stefoski D, Quandt FN. Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann Neurol. 1995 May;37(5):684.</citation>
    <PMID>7755367</PMID>
  </reference>
  <reference>
    <citation>Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 1994 Jun;44(6):1054-9.</citation>
    <PMID>8208399</PMID>
  </reference>
  <reference>
    <citation>Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol. 1994 Mar;51(3):292-6.</citation>
    <PMID>8129642</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, Bertelsmann FW, Koetsier JC. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci. 1993 Jun;116(2):220-6.</citation>
    <PMID>8336169</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992 Aug;32(2):123-30.</citation>
    <PMID>1510353</PMID>
  </reference>
  <reference>
    <citation>Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology. 1991 Sep;41(9):1344-8.</citation>
    <PMID>1891078</PMID>
  </reference>
  <reference>
    <citation>Polman CH, van Diemen HA, van Dongen MM, Koetsier JC, van Loenen AC, van Walbeek HK. 4-Aminopyridine in multiple sclerosis. Ann Neurol. 1990 Oct;28(4):589.</citation>
    <PMID>2082971</PMID>
  </reference>
  <reference>
    <citation>Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1990 Feb;27(2):186-92.</citation>
    <PMID>2317014</PMID>
  </reference>
  <reference>
    <citation>Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the &quot;McDonald Criteria&quot;. Ann Neurol. 2005 Dec;58(6):840-6. Review.</citation>
    <PMID>16283615</PMID>
  </reference>
  <reference>
    <citation>Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983 Aug-Sep;60(3):353-62.</citation>
    <PMID>6631441</PMID>
  </reference>
  <reference>
    <citation>Vollmer T, Henney HR 3rd. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Clin Ther. 2009 Oct;31(10):2206-14. doi: 10.1016/j.clinthera.2009.10.008.</citation>
    <PMID>19922891</PMID>
  </reference>
  <reference>
    <citation>Vollmer T, Blight AR, Henney HR 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther. 2009 Oct;31(10):2215-23. doi: 10.1016/j.clinthera.2009.10.007.</citation>
    <PMID>19922892</PMID>
  </reference>
  <reference>
    <citation>Beck RW, Ruchman MC, Savino PJ, Schatz NJ. Contrast sensitivity measurements in acute and resolved optic neuritis. Br J Ophthalmol. 1984 Oct;68(10):756-9.</citation>
    <PMID>6477856</PMID>
  </reference>
  <reference>
    <citation>Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. 1996 May;121(5):547-53.</citation>
    <PMID>8610798</PMID>
  </reference>
  <reference>
    <citation>Farnsworth D. The Farnsworth-Munsell 100-hue and dichotomous tests for color vision. J Opt Soc Am 1943;33:568-574.</citation>
  </reference>
  <reference>
    <citation>Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, Song SK, Cross AH. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009 Mar 24;72(12):1077-82. doi: 10.1212/01.wnl.0000345042.53843.d5.</citation>
    <PMID>19307541</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Tutlam NT, Xu J, Shepherd JB, Klawiter EC, Song SK, Cross AH. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology. 2009 Jul 7;73(1):46-52. doi: 10.1212/WNL.0b013e3181aaea32.</citation>
    <PMID>19564583</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Xu J, Tutlam NT, Trinkaus K, Cross AH, Song SK. Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology. 2010 May 25;74(21):1702-10. doi: 10.1212/WNL.0b013e3181e0434d.</citation>
    <PMID>20498438</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Xu J, Tutlam NT, Scully PT, Trinkaus K, Snyder AZ, Song SK, Cross AH. Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology. 2010 May 25;74(21):1694-701. doi: 10.1212/WNL.0b013e3181e042c4. Erratum in: Neurology. 2010 Sep 7;75(10):938.</citation>
    <PMID>20498437</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Xu J, Tutlam NT, Snyder A, Benzinger T, Shimony J, Shepherd J, Trinkaus K, Cross AH, Song SK. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology. 2009 Feb 17;72(7):589-94. doi: 10.1212/01.wnl.0000335766.22758.cd. Epub 2008 Dec 10.</citation>
    <PMID>19073948</PMID>
  </reference>
  <reference>
    <citation>Naismith RT, Shepherd JB, Weihl CC, Tutlam NT, Cross AH. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol. 2009 Aug;66(8):1025-7. doi: 10.1001/archneurol.2009.70.</citation>
    <PMID>19667226</PMID>
  </reference>
  <reference>
    <citation>Vanden Bosch ME, Wall M. Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method. Eye (Lond). 1997;11 ( Pt 3):411-7.</citation>
    <PMID>9373488</PMID>
  </reference>
  <reference>
    <citation>Acorda Therapeutics. AMPRYA package insert (2010).</citation>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <results_first_submitted>May 4, 2016</results_first_submitted>
  <results_first_submitted_qc>January 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2020</results_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>Ampyra</keyword>
  <keyword>Dalfampridine</keyword>
  <keyword>Fampridine</keyword>
  <keyword>Remote Optic Neuritis</keyword>
  <keyword>Contrast Sensitivity</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the John L Trotter Multiple Sclerosis (MS) Clinic at Washington University and through email blasts from the Gateway (St. Louis) MS Chapter. 53 participants meet the pre-screening criteria and signed an informed consent to be screened for the study.</recruitment_details>
      <pre_assignment_details>Patients whose vision did not meet study criteria at the first visit in the affected eye or who had had steroids within 3 months of study entry were considered screen failures (n =7).Treatment group was randomly assigned by the pharmacist using a randomization table generated by a probability model.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group B: Dalfampridine/Placebo</title>
          <description>Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group A: Placebo/Dalfampridine</title>
          <description>Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients that were randomized and included in the per-protocol analysis (compliantly completed 3 visits on assigned treatment).</population>
      <group_list>
        <group group_id="B1">
          <title>Group B: Dalfampridine/Placebo</title>
          <description>Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Group A: Placebo/Dalfampridine</title>
          <description>Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="10.7"/>
                    <measurement group_id="B2" value="50.7" spread="10.2"/>
                    <measurement group_id="B3" value="47.6" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MS Subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Relapsing Remitting MS (RRMS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Progressive MS (SPMS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Episodes of ON</title>
          <units>Number of episodes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline 5% Sloan Chart</title>
          <units>Number of Letters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="2" upper_limit="46"/>
                    <measurement group_id="B2" value="20" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="B3" value="21" lower_limit="2" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores</title>
        <description>Per Protocol Analysis to assess differences in EDTRS 5% Contrast Sensitivity (LogMAR) Scores at visits 2 and 3 Relative to Visit 1 on patients taking Dalfampridine vs Placebo.</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Dalfampridine</title>
            <description>Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo</title>
            <description>Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Placebo</title>
            <description>Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Dalfampridine</title>
            <description>Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores</title>
          <description>Per Protocol Analysis to assess differences in EDTRS 5% Contrast Sensitivity (LogMAR) Scores at visits 2 and 3 Relative to Visit 1 on patients taking Dalfampridine vs Placebo.</description>
          <population>Per protocol analysis</population>
          <units>LogMAR Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eligible eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eligible eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.02"/>
                    <measurement group_id="O2" value="-0.06" spread="0.02"/>
                    <measurement group_id="O3" value="-0.08" spread="0.02"/>
                    <measurement group_id="O4" value="-0.06" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Per protocol Analysis</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in EDTRS between Visits 2 and 3.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.29</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity</title>
        <description>Per Protocol Analysis to assess difference in number of letters on the EDTRS 5% Contrast Sensitivity (LogMAR) Chart scores at visits 2 and 3 Relative to Visit 1</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Group B: Dalfampridine</title>
            <description>Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Placebo</title>
            <description>Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group A: Placebo</title>
            <description>Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Group A: Dalfampridine</title>
            <description>Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity</title>
          <description>Per Protocol Analysis to assess difference in number of letters on the EDTRS 5% Contrast Sensitivity (LogMAR) Chart scores at visits 2 and 3 Relative to Visit 1</description>
          <population>Per protocol analysis</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eligible eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eligible eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1"/>
                    <measurement group_id="O2" value="2" spread="1"/>
                    <measurement group_id="O3" value="4" spread="1"/>
                    <measurement group_id="O4" value="3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1</title>
        <description>Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Improvement from baseline scores.</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <population>Intent To Treat Population, scores from morning and afternoon were averaged.</population>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1</title>
          <description>Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Improvement from baseline scores.</description>
          <population>Intent To Treat Population, scores from morning and afternoon were averaged.</population>
          <units>5% Contrast LogMAR Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.02"/>
                    <measurement group_id="O2" value="0.05" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there will be no difference in the change relevant to baseline (visit 1) in EDTRS 5% contrast sensitivity with dalfampridine vs placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.64</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis for period effect: there will be no difference in the change relevant to baseline (visit 1) in EDTRS 5% contrast sensitivity for those who started on dalfampridine and crossed over to placebo, compared to those who started on placebo and crossed over to dalfampridine.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart</title>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Improvement while on Dalfampridine (not placebo)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Improvement while on Placebo (not dalfampridine)</description>
          </group>
          <group group_id="O3">
            <title>Both</title>
            <description>Improvement when taking Dalfampridine or Placebo (improvement with any treatment)</description>
          </group>
          <group group_id="O4">
            <title>None</title>
            <description>No Improvement on Dalfampridine/Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart</title>
          <units>Percentages of eyes that improved</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Number of Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="4.0" upper_limit="19.0"/>
                    <measurement group_id="O2" value="11.1" lower_limit="4.9" upper_limit="20.7"/>
                    <measurement group_id="O3" value="11.1" lower_limit="4.9" upper_limit="20.7"/>
                    <measurement group_id="O4" value="68.1" lower_limit="56.0" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes That Improved by One-line (5 Letters)</title>
        <description>Percentage of eyes that improved by one-line (5 letters) on the 5% contrast sensitivity chart</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <population>Proportion as the Percent of Eyes Improved by 1 Line</population>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Improvement while on Dalfampridine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Improvement while on Placebo</description>
          </group>
          <group group_id="O3">
            <title>Both</title>
            <description>Improvement on Dalfampridine and Placebo</description>
          </group>
          <group group_id="O4">
            <title>Neither</title>
            <description>No Improvement on Dalfampridine or Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes That Improved by One-line (5 Letters)</title>
          <description>Percentage of eyes that improved by one-line (5 letters) on the 5% contrast sensitivity chart</description>
          <population>Proportion as the Percent of Eyes Improved by 1 Line</population>
          <units>Percent of Eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Number of Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="4.9" upper_limit="20.7"/>
                    <measurement group_id="O2" value="15.3" lower_limit="7.9" upper_limit="25.7"/>
                    <measurement group_id="O3" value="37.5" lower_limit="26.4" upper_limit="49.7"/>
                    <measurement group_id="O4" value="36.1" lower_limit="25.1" upper_limit="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.34</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Evoked Potential P100 Latency Per Treatment Arm</title>
        <description>Visual evoked potential 60min P100 latency on dalfampridine vs. placebo.</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Evoked Potential P100 Latency Per Treatment Arm</title>
          <description>Visual evoked potential 60min P100 latency on dalfampridine vs. placebo.</description>
          <population>per protocol</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" spread="2.4"/>
                    <measurement group_id="O2" value="120.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Odds Ratio Quartile of Visual Field Index</title>
        <description>The Visual Field Index (VFI) is a global index that assigns a number between 1% to 100% based on an aggregate percentage of visual function, with 100% being a perfect age-adjusted visual field.
Probability of falling in the best quartile for visual field (VFI) measures (Q1), relative to the three next quartiles for worse VFIs (Q2-4), while on Dalfampridine vs Placebo. Due to the clustered observations at different times in a cross-over design, the visual field data is not suited to a normal theory model and should not be expressed as a continuous variable. Thus, a categorical model that uses a multinomial distribution for measurement of 4 categories was selected for proper statistical modeling, with results expressed as odds ratios.</description>
        <time_frame>Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - post intervention 1) and Visit 3 (Week 8 - post intervention 2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine Then Placebo</title>
            <description>Weeks 1-3 Dalfampridine 10 mg Twice Daily, Weeks 6-8 Placebo Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Dalfampridine</title>
            <description>Weeks 1-3 Placebo Twice Daily, Weeks 6-8 Dalfampridine 10 mg Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Odds Ratio Quartile of Visual Field Index</title>
          <description>The Visual Field Index (VFI) is a global index that assigns a number between 1% to 100% based on an aggregate percentage of visual function, with 100% being a perfect age-adjusted visual field.
Probability of falling in the best quartile for visual field (VFI) measures (Q1), relative to the three next quartiles for worse VFIs (Q2-4), while on Dalfampridine vs Placebo. Due to the clustered observations at different times in a cross-over design, the visual field data is not suited to a normal theory model and should not be expressed as a continuous variable. Thus, a categorical model that uses a multinomial distribution for measurement of 4 categories was selected for proper statistical modeling, with results expressed as odds ratios.</description>
          <units>Visual Field Index % of normal vision</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eligible eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eligible eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Visit 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.53" spread="29.84"/>
                    <measurement group_id="O2" value="85.38" spread="86.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Intervention 1 (Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.50" spread="28.30"/>
                    <measurement group_id="O2" value="86.65" spread="22.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Intervention 2 (Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.71" spread="28.57"/>
                    <measurement group_id="O2" value="86.00" spread="22.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>Probability of being in the lowest quartile for Visual Field Index deficits.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
            <estimate_desc>Odds Ratio for Visual Field Index</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Color Vision Total Error Score From Baseline Based Upon the Farnsworth Munsell Hue 100 Sort Test (FM100).</title>
        <description>Dalfampridine will change color vision Total Error Scores from baseline on the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 color palettes in the correct order based upon color hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score greater than 500 indicates virtually no color discrimination. An error score of 0 indicates no errors in ordering the hues. A Total Error Score of 0 to 128 could be seen in a normal population.</description>
        <time_frame>Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - postintervention 1) and Visit 3 (Week 8 - post intervention 2)</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Color Vision Total Error Score From Baseline Based Upon the Farnsworth Munsell Hue 100 Sort Test (FM100).</title>
          <description>Dalfampridine will change color vision Total Error Scores from baseline on the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 color palettes in the correct order based upon color hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score greater than 500 indicates virtually no color discrimination. An error score of 0 indicates no errors in ordering the hues. A Total Error Score of 0 to 128 could be seen in a normal population.</description>
          <population>per protocol</population>
          <units>FM100 Total Error Score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" lower_limit="-15.0" upper_limit="-11.0"/>
                    <measurement group_id="O2" value="-10.6" lower_limit="-28.3" upper_limit="-7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dalfampridine Effect on Quality of Life Change From Baseline.</title>
        <description>Dalfampridine treatment will result in change in quality of life. The National Eye Institute Visual Function Questionnaire consists of 25 questions characterizing visual function at home and in the community. Score ranges from 100 (best) to 0 (worst).</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Study participants on dalfampridine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Study participants on placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Dalfampridine Effect on Quality of Life Change From Baseline.</title>
          <description>Dalfampridine treatment will result in change in quality of life. The National Eye Institute Visual Function Questionnaire consists of 25 questions characterizing visual function at home and in the community. Score ranges from 100 (best) to 0 (worst).</description>
          <units>NEI VFQ percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-40.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="0" lower_limit="-35.0" upper_limit="302.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1</title>
        <description>Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 on Dalfampridine vs Placebo. Pelli-Robson is scored based upon the numbers read on the chart converted to LogMAR units. The scale is 0.00 (worst) to 2.35 (best).</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1</title>
          <description>Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 on Dalfampridine vs Placebo. Pelli-Robson is scored based upon the numbers read on the chart converted to LogMAR units. The scale is 0.00 (worst) to 2.35 (best).</description>
          <population>per protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Number of Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.02"/>
                    <measurement group_id="O2" value="0.06" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity</title>
        <description>Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Change in the number of letters able to read while on Dalfampridine and Placebo relative to their baseline scores.</description>
        <time_frame>Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)</time_frame>
        <population>Intent To Treat Population, scores from morning and afternoon were averaged.</population>
        <group_list>
          <group group_id="O1">
            <title>Dalfampridine</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient Assessments while on Dalfampridine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity</title>
          <description>Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Change in the number of letters able to read while on Dalfampridine and Placebo relative to their baseline scores.</description>
          <population>Intent To Treat Population, scores from morning and afternoon were averaged.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1"/>
                    <measurement group_id="O2" value="2.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Only unexpected and and reasonably related events were recorded. Adverse events related to known side effects of dalfampridine (listed in the package insert) or the patients prior medical history are not recorded. There were no events that warranted modification to the consent for the duration of the study. All adverse events (four) occurred while taking dalfmapridine during this cross-over study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dalfampridine</title>
          <description>Participants assigned to received dalfampridine.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants assigned to received placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot study with relatively small number of patients compared to a phase III study. Cross-over design may be inferior to placebo-controlled parallel cohort study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Naismith, MD</name_or_title>
      <organization>Washington Univerisity St. Louis</organization>
      <phone>314-747-5576</phone>
      <email>naismithr@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

